ClinicalTrials.gg
SuspendedNCT06188507Updated Oct 3, 2025

A First Time in Human Study to Evaluate the Safety and Tolerability of GSK3996401 Following Dosing With GSK4347859 in Healthy Participants

A Phase 1 interventional study of GSK4347859 and Placebo in Systemic Lupus Erythematosus, sponsored by GlaxoSmithKline. Suspended at 2 sites in United Kingdom. Open to participants aged 18 Years to 55 Years, including healthy volunteers. Per ClinicalTrials.gov, last updated 2025-10-03.

Sponsored by GlaxoSmithKline · Phase 1, Interventional, and Treatment

Why this study was suspended
The trial was temporarily halted due to findings in new non-clinical studies necessitating further investigation.

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 1
Study type
Interventional
Enrollment
65
Allocation
Randomized
Ages
18 Years to 55 Years
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-17

Among 43 studies in Lupus Erythematosus, Systemic by GlaxoSmithKline — 1 open to participants now, 4 under way, none of them phase 3. Lupus Erythematosus, Systemic · GlaxoSmithKline.

Planned enrollment
24th of 36
65 · median 87
Started
2024
with 3 others
Phase 1
14 of 43
1 open now
Registered
39th of 43
by date

Among the 43 studies in Lupus Erythematosus, Systemic by GlaxoSmithKline, this one is the 24th largest by planned enrollment of the 36 interventional ones that give a count, is one of 4 that started in 2024, is one of 14 in phase 1, and was the 39th registered.

Lupus Erythematosus, Systemic

1,210 studies on the registry are indexed under Lupus Erythematosus, Systemic; 406 are open to participants now.

Browse Lupus Erythematosus, Systemic studies →

Open to participants now

1 of the 43 studies in Lupus Erythematosus, Systemic by GlaxoSmithKline is open now, in 9 countries. Recruiting first, the newest first:

By country, each count listing its studies:

Who these studies take

Of the 284 Lupus Erythematosus, Systemic studies recruiting now, 93 (33%) set no upper age limit and 161 (57%) stop at 75 or younger; 54 take children under 18; 33 take healthy volunteers.

This study: 18 Years to 55 Years · all sexes · healthy volunteers too.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 43 studies in Lupus Erythematosus, Systemic by GlaxoSmithKline, or all of them as a file.
02

Study summary

This is a first time in human (FTiH) study which means that this is the first time that GSK4347859 is given to humans. The study is designed to investigate the safety, tolerability, and concentration of GSK3996401 (the activated form of GSK4347859) in the blood following single ascending doses (Part 1) and multiple ascending doses (Part 2) of GSK4347859 in healthy participants. Part 1 consists of 2 planned cohorts with up to 4 treatment periods in each and is expected to have up to 8 dose levels. Part 2 will investigate 14 days of repeat dosing in 3 cohorts with 3 dose levels.

03

Conditions studied

  • Systemic Lupus Erythematosus

Keywords

  • Lupus
  • GSK4347859
  • GSK3996401
  • Safety
  • First time in human (FTiH)
  • Pharmacokinetics
  • Healthy Participants
04

Who can participate

Ages eligible
18 Years to 55 Years
Sexes eligible
All
Accepts healthy volunteers
Yes

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Participants who are overtly healthy.
  • Participant has a confirmed positive vaccination status for severe acute respiratory syndrome-related Coronavirus (2 SARS-CoV-2) and, if study dosing is during Flu season, influenza vaccines administered at least 30 days prior to dosing in the study.
  • Fitzpatrick skin type I, II or III (Part 2 only).
  • Body weight greater than or equal to (≥) 50 kilogram (kg) and (BMI) within the range 18 -32 kilogram per meter square (kg/m\^2) (inclusive).
  • Male and female of non-.
  • Capable of giving signed .

Exclusion criteria

Exclusion Criteria:

  • History or presence of cardiovascular, respiratory, hepatic, renal, gastrointestinal, endocrine, hematological, psychiatric, or neurological disorders. - Abnormal blood pressure
  • A abnormality at screening.
  • Evidence of active or latent tuberculosis (TB).
  • Symptomatic herpes zoster within 3 months prior to screening
  • (ALT) >1 times (ULN).
  • Total >1.5x ULN [isolated total bilirubin >1.5x ULN is acceptable if total bilirubin is fractionated and direct bilirubin \<35- percentage (%)].
  • History of .
  • Participants with known Corona virus disease-2019 (COVID-19) positive contacts as per local/site Guidelines
  • Prior moderate/severe COVID-19 infection requiring oxygen supplementation or admission to hospital.
  • (s) within 1 month prior to screening or plan to receive such vaccines during the study.
  • Past or intended use of over-the-counter or prescription medication including herbal medications within 7 days prior to dosing
  • The participant has participated in a clinical trial and has received an product within 30 days, 5 half-lives or twice the duration of the biological effect of the investigational product and dosing.
  • Current enrolment or past participation in this clinical study
  • Presence of surface antigen (HBsAg) at screening or within 3 months prior to first dose of study intervention
  • Positive antibody test result at screening or within 3 months prior to first dose of study intervention
  • Positive hepatitis C Ribonucleic acid (RNA) test result at screening or within 3 months prior to first dose of study
  • Positive pre-study drug/alcohol screen
  • Regular use of known drugs of abuse, including tetrahydrocannabinol.
  • Positive (HIV) antibody test
  • Positive smoke breathalyzer levels indicative of smoking history at screening and each in-house admission to the clinical research unit or regular use of tobacco- or nicotine-containing products within 6 months prior to screening.
  • Estimated (eGFR) of less than (\<) 90 (millilitre/minute) mL/min/1.73 m2 and / or Urine Albumin Creatinine (UACR) of >30 milligram per gram (mg/g) at screening
  • A positive confirmation of SARS-CoV-2 infection or signs and symptoms suggestive of SARS-CoV-2 at screening or pre-dose
  • The participant has a phobia to needles
  • An average weekly alcohol intake of > 14 units.

For Part 2:

  • History of benign skin conditions including but not limited to photosensitivity, atopic dermatitis, chronic eczema, psoriasis, urticaria, vitiligo, post-inflammatory hyperpigmentation, or keloid or hypertrophic scaring that in the opinion of the Investigator would impact study participation.
  • History or presence of excessive bleeding or coagulation disorders.
  • History of adverse reaction to local anesthetic.
  • The presence of widespread acne, freckles, naevi, tattoos, birthmarks, piercings, scarring or other skin variations within the proposed Ultraviolet B (UVB) exposure challenge area
  • Direct UV exposure to the areas of the body to be studied within 2 weeks.
  • Unable to refrain from exposure to extended and direct sunlight or use of artificial tanning devices, self-tanning products, sun blocking products or other topical products (including moisturizers and makeup) on the areas of the body to be studied.
Terms in these criteria, in plain language(15)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

BMI (body mass index)

Weight in kilograms divided by height in metres squared. Example: 70 kg and 1.75 m gives 70 ÷ (1.75 × 1.75) ≈ 22.9.

What counts as overweight or obesity differs between countries (some use lower cut-offs), so go by the range the study states.

Childbearing potential

Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).

Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

Clinically significant

Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.

ECG (electrocardiogram)

A recording of the heart’s electrical activity, taken with stickers on the chest, arms and legs. It takes a few minutes and does not hurt.

ALT and AST (liver enzymes)

Two enzymes measured in a routine blood test of the liver. Higher levels can mean the liver is under strain or damaged. SGPT and SGOT are older names for ALT and AST.

Criteria usually give a limit as a multiple of the upper limit of normal (ULN), often higher when cancer has spread to the liver.

ULN (upper limit of normal)

The top of the normal range for a blood test, as set by the laboratory that runs it. Each lab prints its own range next to your result.

“≤ 2.5 × ULN” means the result can be up to two and a half times that top value.

Bilirubin

A yellow substance made when red blood cells are broken down, which the liver clears. A high level can mean a problem with the liver or the bile ducts.

Criteria often allow more for people with Gilbert’s syndrome, a harmless inherited condition that raises bilirubin.

Cancer (malignancy)

Malignancy means cancer. Criteria about another or earlier malignancy ask whether you have had a different cancer, usually within a set number of years.

Some are commonly allowed, such as treated skin cancers other than melanoma and early cancers removed completely — check the exceptions this study lists.

Live vaccines

Vaccines made with a weakened form of the germ, such as measles–mumps–rubella (MMR), chickenpox and yellow fever. They can be risky when the immune system is weakened. Flu injections are not live; the nasal flu spray is.

Investigational drug or device

A drug or device being studied in a clinical trial.

It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.

Hepatitis B tests

Hepatitis B is a virus that infects the liver. These are separate tests: HBsAg positive usually means a current infection (a recent vaccination can briefly cause it too); total anti-HBc (HBcAb) positive means an infection now or in the past; HBV DNA measures how much virus is in the blood.

Some studies accept a past infection if HBV DNA is undetectable, sometimes with antiviral medicine during the study. Check what this study allows.

Hepatitis C tests

Hepatitis C is a virus that infects the liver. An HCV antibody test can stay positive after an infection has cleared (and is occasionally positive without one); an HCV RNA test shows whether the virus is there now.

After treatment, hepatitis C counts as cured when HCV RNA is still undetectable 12 weeks or more after the treatment ended. Studies often accept people cured this way.

HIV

The human immunodeficiency virus, which weakens the immune system.

Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.

GFR and eGFR (kidney filtering)

GFR (glomerular filtration rate) is how much blood the kidneys filter each minute. It is usually estimated from a blood test — eGFR, by formulas such as CKD-EPI or MDRD — and some studies ask for it to be measured directly instead. Usually given in mL/min/1.73 m².

Check the method, the units and the minimum the study states. A value of 90 or above is in the normal-or-high range, but kidney damage can show in other tests too.

05

Study design

Phase
Phase 1
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Sequential assignment
Masking
Double (Participant, Investigator)
Enrollment
65 participants (estimated)

Study arms

  • Experimental
    Part 1: Cohort 1-GSK4347859 or Placebo

    Participants in Part 1 Cohort 1 will receive a single dose level of GSK4347859 dose level 1 or placebo in treatment period 1, followed by GSK4347859 dose levels 2 and 3 or placebo in 3- period dose escalation design. Additionally, there will be an optional 4th treatment period with dose level 4. Followed by a wash out period of at least 7 days between each dose.

    Drug: GSK4347859 · Drug: Placebo

  • Experimental
    Part 1: Cohort 2-GSK4347859 or Placebo

    Participants in Part 1 Cohort 2 will receive a single dose level of GSK4347859 dose level 5 or placebo in treatment period 1, followed by GSK4347859 dose levels 6 and 7 or placebo in 3- period dose escalation design. Additionally, there will be an optional 4th treatment period with dose level 8. Followed by a wash out period of at least 7 days between each dose.

    Drug: GSK4347859 · Drug: Placebo

  • Experimental
    Part 2: Cohort 3-GSK4347859 or Placebo

    Participants in Part 2 Cohort 3 will receive 14 days of repeat doses of GSK4347859 dose level A or placebo.

    Drug: GSK4347859 · Drug: Placebo

  • Experimental
    Part 2: Cohort 4-GSK4347859 or Placebo

    Participants in Part 2 Cohort 4 will receive 14 days of repeat doses of GSK4347859 dose level B or placebo.

    Drug: GSK4347859 · Drug: Placebo

  • Experimental
    Part 2: Cohort 5-GSK4347859 or Placebo

    Participants in Part 2 Cohort 5 will receive 14 days of repeat doses of GSK4347859 dose level C or placebo.

    Drug: GSK4347859 · Drug: Placebo

Interventions

  • DrugGSK4347859

    GSK4347859 will be administered

  • DrugPlacebo

    Placebo will be administered

06

What researchers measure

Primary outcomes

  1. Part 1 - Number of Participants with Adverse Events (AEs) and Serious Adverse Events (SAEs)

    Time frame: Up to Day 15

  2. Part 2 - Number of Participants with Adverse Events (AEs) and Serious Adverse Events (SAEs)

    Time frame: Up to Day 30

  3. Part 1 - Number of Participants with Clinically Significant Changes in Haematology

    Time frame: Up to Day 15

  4. Part 2 - Number of Participants with Clinically Significant Changes in Haematology

    Time frame: Up to Day 30

  5. Part 1 - Number of Participants with Clinically Significant Changes in Clinical Chemistry

    Time frame: Up to Day 15

  6. Part 2 - Number of Participants with Clinically Significant Changes in Clinical Chemistry

    Time frame: Up to Day 30

  7. Part 1 - Number of Participants with Clinically Significant Changes in Laboratory Values for Urinalysis

    Time frame: Up to Day 15

  8. Part 2 - Number of Participants with Clinically Significant Changes in Urinalysis

    Time frame: Up to Day 30

  9. Part 1 - Number of Participants with Clinically Significant Changes in Vital Signs

    Time frame: Up to Day 15

  10. Part 2 - Number of Participants with Clinically Significant Changes in Vital Signs

    Time frame: Up to Day 30

  11. Part 1 - Number of Participants with Clinically Significant Changes in 12 Lead Electrocardiogram Readings

    Time frame: Up to Day 15

  12. Part 2 - Number of Participants with Clinically Significant Changes in 12 Lead Electrocardiogram Readings

    Time frame: Up to Day 30

  13. Part 1 - Number of Participants with Clinically Significant Changes in 24 Hour Telemetry

    Time frame: Up to Day 2

  14. Part 2 - Number of Participants with Clinically Significant Changes in 24 Hour Telemetry

    Time frame: Up to Day 15

Secondary outcomes

  1. Part 1 - Maximum observed plasma concentration (Cmax) of GSK3996401 following administration of GSK4347859

    Time frame: Up to Day 3

  2. Part 1 - Time to maximum observed plasma concentration (Tmax) of GSK3996401 following administration of GSK4347859

    Time frame: Up to Day 3

  3. Part 1 - Apparent terminal half-life (t½) of GSK3996401 following administration of GSK4347859

    Time frame: Up to Day 3

  4. Part 1 - Area under the concentration-time curve from zero to last quantifiable concentration [AUC(0-t)] of GSK3996401 following administration of GSK4347859

    Time frame: Up to Day 3

  5. Part 1 - Area under the concentration-time curve from time zero to infinity [AUC(0-∞)] of GSK3996401 following administration of GSK4347859

    Time frame: Up to Day 3

  6. Part 1 - Area under the concentration-time curve over each dosing interval [AUC(0-tau)] of GSK3996401 following administration of GSK4347859

    Time frame: Up to Day 3

  7. Part 1 - Area under the concentration-time curve from time zero to 24 hours after dosing [AUC(0-24)] of GSK3996401 following administration of GSK4347859

    Time frame: Up to Day 3

  8. Part 1 - Observed trough concentrations (Ctrough) of GSK3996401 following administration of GSK4347859

    Time frame: Up to Day 3

  9. Part 2 - Cmax of GSK3996401 following administration of single and repeat doses of GSK4347859

    Time frame: Up to Day 15

  10. Part 2 - Tmax of GSK3996401 following administration of single and repeat doses of GSK4347859

    Time frame: Up to Day 15

  11. Part 2 - Area under the concentration-time curve from time zero to 24 hours after dosing [AUC(0-24)] of GSK3996401 following administration single and repeat doses of GSK4347859

    Time frame: Up to Day 15

  12. Part 2 - Observed trough concentrations (Ctrough) of GSK3996401 following administration of GSK4347859

    Time frame: Up to Day 15

  13. Part 2 - Area under the concentration-time curve over each dosing interval [AUC(0-tau)] of GSK3996401 following administration of GSK4347859

    Time frame: Up to Day 15

07

Study locations

2 sites
  • GSK Investigational Site
    Cambridge, CB2 2GG, United Kingdom
  • GSK Investigational Site
    Nottingham, NG11 6JS, United Kingdom
08

References and documents

Individual participant data

Plan to share: Yes — Qualified researchers may request access to anonymized individual patient-level data (IPD) and related study documents of the eligible studies via the Data Sharing Portal. Details on GSK's data sharing criteria can be found at: https://www.gsk.com/en-gb/innovation/trials/data-transparency/

Supporting information: Study protocol, Statistical analysis plan, Informed consent form, Clinical study report

Time frame: Anonymized IPD will be made available within 6 months of publication of primary, key secondary and safety results for studies in product with approved indication(s) or terminated asset(s) across all indications.

Access criteria: Anonymized IPD is shared with researchers whose proposals are approved by an Independent Review Panel and after a Data Sharing Agreement is in place. Access is provided for an initial period of 12 months but an extension may be granted, when justified, for up to 6 months.

Data sharing details ↗ · www.gsk.com

No publications or documents are linked to this record.

09

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reached

Started Jan 2024 (actual). Primary completion is estimated for Jul 2026, 30 months after the start.

How these figures are worked out, and which studies are left out of them.

Registered
Dec 19, 2023
First posted
Jan 3, 2024
StartActual
Jan 12, 2024
Primary completionEst.
Jul 14, 2026
CompletionEst.
Jul 14, 2026
Last update
Oct 3, 2025
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Oct 3, 2025, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT06188507
Lead sponsor
GlaxoSmithKline
Responsible party
Sponsor
First posted
Jan 3, 2024
Start date
Jan 12, 2024
Primary completion
Jul 14, 2026 (estimated)
Completion
Jul 14, 2026 (estimated)
Last update
Oct 3, 2025

Study contacts

GSK Clinical Trials
study director · GlaxoSmithKline

Oversight

Data monitoring committee
Yes
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is suspended, as verified in Sep 2025. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion